- Conditions
- Melanoma
- Interventions
- Talimogene laherparepvec, Pembrolizumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 10
- States / cities
- Santa Barbara, California • Newark, Delaware • Orlando, Florida + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2257–2280
of 13,800
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Veno-occlusive Disease
- Interventions
- Defibrotide, Best Supportive Care
- Drug · Other
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 1 Month and older
- Enrollment
- 372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more
- Conditions
- Healthy Volunteer
- Interventions
- Etrolizumab, Prefilled Auto-injector (Rotaject)
- Drug · Device
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Cypress, California • Dallas, Texas
- Conditions
- Migraine
- Interventions
- Elismetrep, Placebo
- Drug
- Lead sponsor
- TriGemX Bio, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 72
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 64 more
- Conditions
- Hypertension, Impaired Glucose Tolerance
- Interventions
- AR9281, Placebo
- Drug
- Lead sponsor
- Arete Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 30
- States / cities
- Mobile, Alabama • Muscle Shoals, Alabama • Anaheim, California + 26 more
- Conditions
- Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Interventions
- ALN-BCAT, Pembrolizumab
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 12 more
- Conditions
- Advanced Solid Tumors
- Interventions
- DB-1311, Lopinavir and Ritonavir Tablets, itraconazole, Enzalutamide, Abiraterone
- Drug
- Lead sponsor
- DualityBio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 862 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 28
- States / cities
- Tucson, Arizona • Los Angeles, California • Santa Monica, California + 21 more
- Conditions
- Metabolic Disorders
- Interventions
- REGN1500, placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 4
- States / cities
- Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more
- Conditions
- Morbid Obesity
- Interventions
- 3.5 mm vs 4.8 mm Stapler During Laparoscopic Gastric Bypass
- Procedure
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 6
- States / cities
- Orange, California • Tampa, Florida • Boston, Massachusetts + 3 more
- Conditions
- Baseline Thrombocytopenia
- Interventions
- Not listed
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations, Telangiectasia, Epistaxis, GastroIntestinal Bleeding, Cerebral Arteriovenous Malformations, Vascular Malformation
- Interventions
- Not listed
- Lead sponsor
- Cure HHT
- Other
- Eligibility
- Not listed
- Enrollment
- 10,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2033
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
- Conditions
- HIV-1
- Interventions
- Maraviroc, Emtricitabine/tenofovir, darunavir/ritonavir 800/100 mg, placebo for emtricitabine/tenofovir, placebo for maraviroc
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 813 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 84
- States / cities
- Birmingham, Alabama • Hobson City, Alabama • Hayward, California + 45 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- INNO-206
- Drug
- Lead sponsor
- CytRx
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Billings, Montana • Albany, New York + 4 more
- Conditions
- Migraine Headache
- Interventions
- Erenumab 70 mg, Erenumab 140 mg, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 32
- States / cities
- Cerritos, California • Colton, California • Los Angeles, California + 28 more
- Conditions
- Uveitic Macular Edema
- Interventions
- Vamikibart, Sham
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Lakewood, Colorado • St. Petersburg, Florida + 13 more
- Conditions
- Hypertension, Stage 2 Hypertension, Diabetes
- Interventions
- Valturna, Amlodipine, Chlorthalidone, Placebo of Valturna Tablet, Placebo Capsule
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 975 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 95
- States / cities
- Athens, Alabama • Florence, Alabama • Huntsville, Alabama + 78 more
- Conditions
- Multiple Myeloma
- Interventions
- JNJ-79635322, Teclistamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 35 more
- Conditions
- HIV Infection
- Interventions
- emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), abacavir (ABC)/lamivudine (3TC)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 73
- States / cities
- Little Rock, Arkansas • Beverly Hills, California • Fountain Valley, California + 47 more
- Conditions
- Recurrent or Metastatic Solid Tumors
- Interventions
- Ifinatamab deruxtecan
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Whittier, California • Skokie, Illinois + 13 more
- Conditions
- Cirrhosis, Ascites
- Interventions
- alfapump system
- Device
- Lead sponsor
- Sequana Medical N.V.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 5
- States / cities
- San Francisco, California • Rochester, Minnesota • Dallas, Texas + 2 more
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Interventions
- Pemvidutide, Placebo
- Drug · Other
- Lead sponsor
- Altimmune, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 61
- States / cities
- Dothan, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more
- Conditions
- Solid Tumors
- Interventions
- ONT-10
- Biological
- Lead sponsor
- Cascadian Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Schizophrenia, Bipolar
- Interventions
- This is an observational study model that is family based
- Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 3,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2019
- U.S. locations
- 6
- States / cities
- Hartford, Connecticut • Chicago, Illinois • Baltimore, Maryland + 2 more
- Conditions
- Antibody-mediated Rejection
- Interventions
- Felzartamab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Orange, California • San Bernardino, California + 20 more